Skip to main content

SomaLogic Raises $10M

NEW YORK (GenomeWeb News) – SomaLogic has raised $10 million in equity financing, the company said in a document filed with the US Securities and Exchange Commission on Tuesday.

The Boulder, Colo.-based protein biomarker discovery and clinical diagnostics company declined to comment on the financing. In its Form D document, it said that it had one investor in the round but did not identify the investor. SomaLogic did not say how proceeds will be used.

The privately held firm raised $19.5 million in 2003 in a Series C private financing round. In 2009, it received a $15 million investment from Quest Diagnostics as part of a diagnostic development deal, and in late 2003, SomaLogic received two investments totaling $11 million from two Japanese firms.

Last week, the company and Agilent Technologies announced a deal to expand SomaLogic's SOMAscan protein biomarker discovery platform.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.